|
|
|
|
FOCUS ON TRANSLATIONAL RESEARCH |
|
|
|
A conversation with Maurits Geerlings, M.D., and Jacek Lubelski, Ph.D., NanoCell Therapeutics | If the science holds, the implications include substantial cost reduction and putting engineered T cell therapies within reach of patients anywhere in the world. | |
|
|
| LC/MS Method For Measurement In Human Plasma | Video | Aliri Bioanalysis | According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches. |
|
|
| Enhancing Stereo Microscopy With Superior 3D Imaging And Depth Of Field | Article | By Dr. Daniel Kiper, Claudia Muller, Daniel Goeggel, Anja Schue, Danaher Life Sciences | FusionOptics technology enables stereo microscopes that mix high resolution and depth of field to provide a 3D perception of samples. Images with higher resolution allow perception with an up to three times larger depth of field. |
|
|
| Optimized Urine Liquid Biopsy Workflow | Application Note | QIAGEN | Urine-derived cell-free DNA is revolutionizing liquid biopsy research to offer a non-invasive, accessible tool for early disease detection, monitoring, and comprehensive diagnostics across oncology. |
|
|
|
|
| Webinar: Development of an Off-the-Shelf γδ T-Cell Platform for Allogenic Cell Therapies | Unlock the future of cell therapy with Miltenyi! Join our webinar to explore how γδ T cells are driving next-generation, off-the-shelf allogeneic therapies. Discover their unique advantages, learn engineering strategies to overcome immunological hurdles, and see a real-world case study of a successful therapeutic candidate. Don’t miss this chance to gain insights into the future of immuno-oncology. Click here to learn more. |
|
|
TRANSLATIONAL RESEARCH SOLUTIONS |
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|
